• The UNITE platform is based in part on lysosomal targeting technology which results in enhanced antigen presentation and a balanced T cell response. (biospace.com)
  • These tumor specific antigens are the result of mutations that cancer cells undergo, and in many cases that involve viral carcinogens, viral antigens. (oncolink.org)
  • Monoclonal antibodies developed against immunogenic proteins (Tumor Specific Antigens/TSA's) that are expressed in human cancers, display a unique behavioral pattern. (jcancer.org)
  • Mabs capable of targeting the malignancies noted above were produced following immunization of BALBc mice with the Tumor Specific Antigens. (jcancer.org)
  • The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. (stockhouse.com)
  • Tumor-specific antigens (TSAs) are unique to tumor cells. (msdmanuals.com)
  • Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. (biospace.com)
  • Arlen M, Arlen P, Tsang A, Wang X, Gupta R. The Therapeutic Value of Monoclonal Antibodies Directed Against Immunogenic Tumor Glycoproteins. (jcancer.org)
  • The monoclonals (mAbs) that we have developed against specific immunogenic tumor membrane proteins have been studied in detail. (jcancer.org)
  • Enforced expression of the transcription factors PU.1, IRF8, and BATF3 (PIB) was sufficient to induce the cDC1 phenotype in 36 cell lines derived from human and mouse hematological and solid tumors. (lu.se)
  • Emerging evidence indicates that Trm cells develop in human solid cancers and play a key role in controlling tumor growth. (lifeboat.com)
  • The monoclonals, so produced, were not only more efficient in controlling tumor growth but minimized the development of a HAMA response. (jcancer.org)
  • The iBioModulator also has been used by scientists at the Fraunhofer USA Center for Molecular Biotechnology to improve the solubility and stability not only of recombinant vaccine antigens, but other proteins as well. (globenewswire.com)
  • One insight is the identification of tumor antigens (small proteins recognized as "foreign" by the immune system) that stimulate the T-cells of the immune system. (oncolink.org)
  • Tripartite Motif Containing 13 (TRIM13), a member of TRIM proteins, is deleted in multiple tumor types, especially in B-cell chronic lymphocytic leukemia and multiple myeloma. (cancerindex.org)
  • This includes the early recognition of these immunogenic membrane proteins that can serve as diagnostic markers, and the targeting of such markers for the destruction of the tumor, primarily thru ADCC. (jcancer.org)
  • These tumor proteins, when first defined, were referred to as tumor associated antigens. (jcancer.org)
  • Monoclonals that we were able to develop from tumor specific proteins derived from colon and pancreas cancer were found capable of targeting those tumors to induce apoptosis. (jcancer.org)
  • However, cDC1 can be compromised in cancer patients and some cancer cells lack these antigen-presenting proteins on their surface, impacting immunotherapy response. (lu.se)
  • In the second part of this review, we provide evidence that frequent exercise enhances-rather than suppresses-immune competency, and highlight key findings from human vaccination studies which show heightened responses to bacterial and viral antigens following bouts of exercise. (frontiersin.org)
  • ITI's UNITE platform could potentially have broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens, and antigen-derived antibodies as biologics. (biospace.com)
  • Here, we demonstrate that NK cells (haNKs) engineered to express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of human and murine head and neck cancer cells at low effector-to-target ratios in a PD-L1-dependent fashion. (elifesciences.org)
  • Here, we describe the pre-clinical in vitro and in vivo study of irradiated haNK cells engineered to express a second-generation chimeric antigen receptor (CAR) targeting programmed death-ligand 1 (PD-L1). (elifesciences.org)
  • Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
  • Chimeric antigen receptor T cells (CARTs) are a novel cell-based therapy designed to direct host-derived T-cells against cancer cells through tumor-specific surface receptors. (medpagetoday.com)
  • Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions and possibly cure patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with poor prognosis and no standard therapeutic options. (medpagetoday.com)
  • reported laser irradiation of photodynamic therapy (PDT) to treat mice subcutaneously inoculated with CT26.CL25 colon carcinoma cells inducing local remission and antigen-specific immune response systemically, promoting regression of a remote and untreated tumor 9 . (medicalrecords.com)
  • However CT26.CL25 cells are artificially transduced with the lacZ gene to stably express a tumor antigen (beta-gal). (medicalrecords.com)
  • The phenomenon promoting regression of a remote and untreated tumor was not observed when they employed CT26 wild type (CT26WT) undifferentiated colon carcinoma cells, which are beta-gal negative parental carcinoma of CT26.CL25 cells. (medicalrecords.com)
  • This is surprising because many reports showed PDT could induce the immune response against locally inoculated CT26WT colon carcinoma cells 10 , 11 , 12 . (medicalrecords.com)
  • These carcinoma cells are a clone of the N-nitoroso-N-methylurethan (NMU)-induced grade IV carcinoma, which is rapidly-growing and readily-metastasizing 13 . (medicalrecords.com)
  • RT-induced damage to cancer cells leads to different outcomes, such as survival, senescence, or death. (nature.com)
  • Furthermore, inflammatory mediators released by irradiated dying cells can attract and regulate immune cells in the tumor microenvironment (TME), further killing cancer cells. (nature.com)
  • In addition, tumor-associated antigens (TAAs) produced by irradiated tumor cells can be captured by antigen-presenting cells (APCs) in the TME and presented to T cells. (nature.com)
  • Induced-self antigen is a marker of abnormal self, which can be recognized upon infected (in particular, virus-infected) and transformed cells. (wikipedia.org)
  • Therefore, the recognition of "induced self" is an important strategy for surveillance of infection or tumor transformation - it results in elimination of the affected cells by activated NK cells or other immunological mechanisms. (wikipedia.org)
  • Similarly γδ T cells can recognize induced-self antigens expressed on cells under stress conditions. (wikipedia.org)
  • As tumors are very often capable of escaping the immune system by many ways, upregulation of specific ligands on the tumor cells could mount effective immune mechanisms able to eliminate these cells. (wikipedia.org)
  • This phenomenon could be offset by a dual-CAR system incorporating both an activating CAR against the cognate tumor antigen and an NK self-recognizing inhibitory CAR that transferred a 'don't kill me' signal to NK cells upon engagement with their TROG + siblings. (nature.com)
  • Fig. 1: CAR19-mediated trogocytosis in NK cells cocultured with CD19 + tumor targets. (nature.com)
  • Fig. 5: Expression of an iCAR by NK cells reduced fratricide and exhaustion induced by aCAR. (nature.com)
  • Our data indicate that certain GSL antigens, especially SGGLs, GD3, and OAc-GD3, are expressed in neural tumor cells and may be considered as tumor-associated antigens that represent important biomarkers for neural tumors. (karger.com)
  • Binding of complement to a foreign substance, or antigen, amplifies and augments the body's innate immune system by means of its role as an opsonin (a factor that enhances phagocytosis of unwanted particles) and as a chemoattractant (a factor that recruits cells to areas of inflammation). (medscape.com)
  • The generation of receptors specific for antigens is a unique and complex process that generates 10 12 specific receptors for each cell type of the adaptive immune system, including T and B cells. (medscape.com)
  • Various cell types can process and present these antigens to T cells, or antigens may be soluble and bound to B-cell receptors. (medscape.com)
  • We previously established that an unidentified factor, or factors, present in ovarian tumor ascites fluids reversibly inhibited the activation of T cells by arresting the T-cell signaling cascade. (aacrjournals.org)
  • Regardless of the therapeutic approach, the heterogeneity of pancreatic cancer cells and the complexity of its tumor microenvironment contribute to the emergence of drug resistance. (frontiersin.org)
  • The 131 I radiolabel generally clears rapidly from the tumor after internalization and subsequent degradation of the bivalent l -amino acid peptide ( l -a.a. peptide) in the tumor cells. (snmjournals.org)
  • Monoclonal antibodies (mAbs) directed against tumor-associated antigens have excellent characteristics to target tumor cells selectively ( 1 - 3 ). (snmjournals.org)
  • Unfortunately, after internalization and degradation of the 131 I-labeled peptide in the lysosomes, the metabolite 131 I-Tyr is rapidly cleared from tumor cells ( 12 - 15 ). (snmjournals.org)
  • The roles of antigen-specificity, responsiveness to TGFβ and APC subsets in tumour-induced expansion of regulatory T cells. (imperial.ac.uk)
  • Here, we demonstrated that intradermal administration of clinically relevant vaccines efficiently induces Trm cells specific for tumor-specific and self-antigens that accumulate in vaccinated and non-vaccinated skin. (lifeboat.com)
  • Interestingly, vaccination-induced Trm cells strongly suppress the growth of melanoma, independently of circulating CD8 T cells, and were able to infiltrate melanoma tumors. (lifeboat.com)
  • Therefore, our work highlights the therapeutic potential of vaccination-induced Trm cells to achieve potent protection against skin malignancies. (lifeboat.com)
  • However, the specific contribution of Trm cells to anti-tumor immunity is incompletely understood. (lifeboat.com)
  • Vaccination-induced Trm cells were largely resistant to in vivo intravascular staining and antibody-dependent depletion. (lifeboat.com)
  • 8-10 Long-lasting protective immunity relies on the efficient establishment of long-lived memory CD8 + T cells, which have the potential to eradicate primary and disseminated tumors. (lifeboat.com)
  • Tumors frequently induce immature myeloid cells (iMC), which suppress specific and unrelated cytotoxic T lymphocyte (CTL) responses and are termed myeloid derived suppressor cells (MDSC). (mdc-berlin.de)
  • Rather than attempting to determine the exact antigen on the cancer cells themselves, an alternative approach has been to isolate and to study the immunogobulins that our bodies have produced in recognition of these foreign antigens. (oncolink.org)
  • Recently, cells called antigen presenting cells (APCs) were discovered to play a pivotal role in the immune response. (oncolink.org)
  • These cells, such as dendritic cells, process foreign antigens and then present them to T-cells, causing their intense activation. (oncolink.org)
  • In fact, immature dendritic cells can actually cause the suppression of responses to antigen. (oncolink.org)
  • Hence, it would help create more T-cells that react to the antigen presented. (oncolink.org)
  • As noted above, a more vigorous dendritic cell presentation of antigens could trigger the immune response by T-cells. (oncolink.org)
  • Co-stimulatory molecules are presenting along with the antigen by APCs to induce an aggressive response by the T-cells. (oncolink.org)
  • This approach is based on the view that immune stimulation is primarily mediated by APCs rather than the tumor cells themselves. (oncolink.org)
  • TSPO is overexpressed in primary brain tumors and has been shown to correlate with the malignancy of the tumor cells. (uni-regensburg.de)
  • Cancer/testis antigen MAGEC2 (also known as HCA587) is highly expressed in a wide variety of tumors and plays an active role in promoting growth and metastasis of tumor cells. (biomedcentral.com)
  • Co-immunoprecipitation assay was applied for detecting the endogenous interaction of MAGEC2 and TRIM28 in tumor cells. (biomedcentral.com)
  • We demonstrate that MAGEC2 interacts with TRIM28 in melanoma cells and MAGEC2 expression in tumor cells depends on the expression of TRIM28. (biomedcentral.com)
  • The expression level of MAGEC2 protein was significantly reduced when TRIM28 was depleted in tumor cells, and no changes were observed in MAGEC2 mRNA level. (biomedcentral.com)
  • Mechanistic studies indicate that the regulatory role of TRIM28 on MAGEC2 protein expression in tumor cells depends on proteasome-mediated pathway. (biomedcentral.com)
  • In this study, we found that expression of MAGEC2 protein in tumor cells depends on the expression of TRIM28, a reduction in the level of endogenous TRIM28 expression in melanoma cells resulting in significantly decreased expression of MAGEC2 protein. (biomedcentral.com)
  • TRIM13 inhibited cell proliferation and induced cell apoptosis by regulating NF-κB pathway in non-small-cell lung carcinoma cells. (cancerindex.org)
  • Treatment of syngeneic tumors resulted in CD8 and PD-L1-dependent tumor rejection or growth inhibition and a reduction in myeloid cells endogenously expressing high levels of PD-L1. (elifesciences.org)
  • T cell-based immunotherapy, such as immune checkpoint blockade or adoptive T cell transfer, is limited by the ability of T cells to detect major histocompatibility complex (MHC)-presented antigen by tumor cells. (elifesciences.org)
  • Natural killer (NK) cell-based immunotherapy may overcome genetic mechanisms of resistance to T cell-based immunotherapy through antigen- and MHC-independent recognition of malignant cells. (elifesciences.org)
  • However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
  • Various biological processes including immunoreaction of infection, tumor prevention, and human aging could cause telomere damage, tumor-related stress responses, and T regulatory (Treg) cells activation, which even trigger T cell senescence showing the distinctive phenotypic and functional alternation [ 9 , 10 ]. (hindawi.com)
  • Reprogramming is a promising treatment, which redifferentiates T-induced pluripotent stem cells (T-IPSCs) into naïve and cytotoxic T cells or dedifferentiates within their own lineage [ 13 ]. (hindawi.com)
  • In preclinical studies, ITI-4000, a DNA vaccine targeting EBNA1, demonstrated robust activation of anti-tumor CD4 and CD8 T cells in vivo and promoted tumor infiltration with activated TNFα-producing CD8 T cells. (biospace.com)
  • Intratumoral IL-12-producing dendritic cells and iNOS-producing macrophages were also induced by the vaccine. (biospace.com)
  • Targeting EBNA1 allows for an immunotherapeutic approach by exploiting the potential of the immune system to recognize tumor cells through their expression of this viral antigen. (biospace.com)
  • We report that the ITI-4000 induced IFNγ- and TNFα-producing effector memory CD4 T and CD8 T cells, with complete rejection of EBNA1-expressing tumors observed in 50% of mice. (biospace.com)
  • This specific construct consists of equal quantities of CD4+/CD8+ CARTs which are transduced separately after apheresis and directed against CD-19 on tumor cells subsequently in a 1:1 infusion. (medpagetoday.com)
  • 1991. Control of 1,2-dimethylhydrazine-induced crypt hyperplasia by naturalkiller cells and its relevance to carcinogenics. (cdc.gov)
  • Decreased antigen presentation contributes to the ability of cancer cells to evade the immune system. (lu.se)
  • Within 9 days of reprogramming, tumor-APCs acquired transcriptional and epigenetic programs associated with cDC1 cells. (lu.se)
  • Reprogramming restored the expression of antigen presentation complexes and costimulatory molecules on the surfaces of tumor cells, allowing the. (lu.se)
  • Human primary tumor cells could also be reprogrammed to increase their capability to present antigen and to activate patient-specific tumor-infiltrating lymphocytes. (lu.se)
  • Our approach serves as a platform for the development of immunotherapies that endow cancer cells with the capability to process and present endogenous tumor antigens. (lu.se)
  • Reprogramming cancer cells to antigen-presenting cells. (lu.se)
  • Many tumor cells produce antigens, which may be released in the bloodstream or remain on the cell surface. (msdmanuals.com)
  • Tumor-associated antigens (TAAs) are relatively restricted to tumor cells. (msdmanuals.com)
  • However, several antigens with selective expression on the surface of tumor cells are not associated with the major histocompatibility complex and may be candidates for therapeutic targeting. (msdmanuals.com)
  • References Many tumor cells produce antigens, which may be released in the bloodstream or remain on the cell surface. (msdmanuals.com)
  • By using direct reprogramming strategies, I could induce the expression of tumor antigens on the surface of cancer cells, making them visible to the immune system again. (lu.se)
  • We focused particularly on harnessing reprogramming, or direct cellular reprogramming, to induce antigen presentation in cancer cells. (lu.se)
  • when it comes to cancer they are critical as they present tumor antigens to the killer cells of the immune system and orchestrate the anti-tumor immune response. (lu.se)
  • Direct reprogramming strategies with cDC1-specific factors can induce antigen-presentation in cancer cells, making cancer cells visible to the immune system and easier to fight. (lu.se)
  • Immunotherapies with antibody-drug-conjugates (ADC) and CAR-T cells, targeted at tumor surface antigens (surfaceome), currently revolutionize clinical oncology. (lu.se)
  • My Ph.D. studies have focused on restoring anti-tumor immunity with dendritic cell reprogramming strategies. (lu.se)
  • Fig. 3: Impact of TROG-antigen acquisition on CAR-NK cell phenotype and function in vivo. (nature.com)
  • Mainly analyzed by in vitro assays in tumor transplantation models, little is known about their function in autochthonous tumor models in vivo. (mdc-berlin.de)
  • None of the iMC from the different tumor models suppressed CTL responses in adoptive cell transfer experiments, unless GM-CSF was provided in vivo. (mdc-berlin.de)
  • Area A will delineate the diagnostic potential of TSPO imaging by means of positron emission tomography (PET) in brain tumors in vivo and will enable the complementary characterization of brain tissue in vitro to delineate the neurobiological characteristics underlying TSPO PET labeling in the human brain. (uni-regensburg.de)
  • Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform. (stockhouse.com)
  • In addition to acquiring improved antigen presentation, tumor-APCs had impaired tumorigenicity in vitro and in vivo. (lu.se)
  • All sera had high titers of antibodies of the IgM isotype against SGPG (titers over 1:3,200), especially in tumors such as meningiomas, germinomas, orbital tumors, glioblastomas, medulloblastomas, and subependymomas. (karger.com)
  • It is required by FDA that the potential effects of tumor control and toxicity be defined using the naked antibodies produced under GMP conditions, In those situations where patients with recurrent malignancies are to be studied we have come to realize that a number of factors can influence the response to monoclonal therapy. (jcancer.org)
  • They can also exhibit antibodies to antigens associated with pemphigus vulgaris (desmoglein 3, 130-kd) and pemphigus foliaceus (desmoglein 1, 160-kd), as well as several others, including epiplakin. (medscape.com)
  • Host Response to Tumors The immune response to foreign antigens consists of Humoral mechanisms (eg, antibodies) Cellular mechanisms (See also Tumor Antigens. (msdmanuals.com)
  • Although RT is an important modality for cancer treatment, the consequential changes caused by RT in the tumor microenvironment (TME) have not yet been fully elucidated. (nature.com)
  • Thus, addressing the presence of immunosuppressive myeloid cell populations in the periphery and tumor microenvironment of patients with cancer is likely to be required for effective NK cell-based immunotherapy. (elifesciences.org)
  • However, target identification warrants a better understanding of the surfaceome and how it is modulated by the tumor microenvironment. (lu.se)
  • One limitation of the study is that the tumor model used is not a clinically relevant tumor, and instead represents an artificially-induced cancerous state in the subject mice. (medicalrecords.com)
  • Tumors shrank in 6 mice of 11 mice in the aFP group and 8 mice of 11 mice in the aFP + anti-PD-1 group, but such shrinkage occurred in only 1 mouse (9%) from the anti-PD-1 group or does not occur in the control group (Fig. 1b ). (medicalrecords.com)
  • The uptake and retention in the tumor of 111 In-/ 125 I-labeled bivalent peptides ( l -a.a. peptide and d -a.a. peptide) were studied in female BALB/c athymic mice with subcutaneous SK-RC-52 RCC tumors. (snmjournals.org)
  • Tumors were pretargeted with the bispecific monoclonal antibody (bs-mAb) G250xDTIn-1 and, 72 h later, mice were injected intravenously with one of both radiolabeled peptides. (snmjournals.org)
  • The effect of bs-mAb-diDTPA-bs-mAb (DTPA is diethylenetriaminepentaacetic acid) bridging at the tumor cell surface on the internalization of the bs-mAb-diDTPA complex was investigated in SK-RC-52 tumor-bearing mice. (snmjournals.org)
  • It produced tumor-free survival of mice immunized with the E7 iBioModulator antigen. (globenewswire.com)
  • ROCKVILLE, Md.--( BUSINESS WIRE )-- Immunomic Therapeutics , Inc. will present data on its investigational nucleic acid platform, UNITE (UNiversal Intracellular Targeted Expression), that elicits potent immune responses and inhibits tumor growth when used with its investigational vaccine, ITI-4000, in mice. (biospace.com)
  • Mice rejecting tumors were protected from rechallenge with CT26-EBNA1, demonstrating that antigen-specific memory was induced in these animals. (biospace.com)
  • Injection of in vitro generated melanoma-derived tumor-APCs into subcutaneous melanoma tumors delayed tumor growth and increased survival in mice. (lu.se)
  • Takashima K, Ito Y, Gonzalez FJ, Nakajima T. Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice. (who.int)
  • By immunoprecipitation, target antigens were identified from skin extracts with molecular weights of 250, 230, 210, and 190 kd. (medscape.com)
  • Immune-inflamed tumors are called hot tumors, while the latter two are collectively referred to as cold tumors, and they respond poorly to immunotherapy. (nature.com)
  • Fig. 4: A lower level of CAR-mediated TROG-antigen expression was associated with improved clinical response to CAR-NK cell-based immunotherapy. (nature.com)
  • Immunotherapy is emerging as a new form to treat cancer by harnessing the activity of cytotoxic CD8 + T lymphocytes (CTLs) that specifically recognize tumor-associated antigens. (lifeboat.com)
  • Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. (elifesciences.org)
  • The identification of immunosuppressive factors within human tumor microenvironments, and the ability to block these factors, would be expected to enhance patients' antitumor immune responses. (aacrjournals.org)
  • Moreover, clinically applicable vaccination strategies that efficiently establish Trm cell responses remain largely unexplored and are expected to strongly protect against tumors. (lifeboat.com)
  • Here we demonstrated that a single intradermal administration of gene- or protein-based vaccines efficiently induces specific Trm cell responses against models of tumor-specific and self-antigens, which accumulated in vaccinated and distant non-vaccinated skin. (lifeboat.com)
  • Vaccination strategies eliciting CTL responses specific for tumor-specific and self-antigens have shown promising results in recent clinical trials. (lifeboat.com)
  • Regardless of the model, tumors produced IL-6 and VEGF but not GM-CSF and induced iMC (CD11b(+)Gr-1(int)) that suppressed CTL responses in vitro. (mdc-berlin.de)
  • However, extremely strong immune responses have been generated using a "boost" to the immune system, provided by viruses that encode antigens similar to the target. (oncolink.org)
  • The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
  • Most humoral responses cannot prevent tumor growth. (msdmanuals.com)
  • Transfusion of autologous tumor-specific CTLs 1-4 and blockade of T cell inhibitory receptors 5-7 have demonstrated to elicit durable clinical benefit in a significant proportion of patients with melanoma, leukemia, lymphoma and other cancers, who failed to respond to conventional treatments. (lifeboat.com)
  • Depending on the context and the cell is type they are expressed, one can view miRNA oncogenic or tumor suppressor activity. (bvsalud.org)
  • Fig. 2: Impact of antigen-induced self-engagement on CAR-NK effector cell phenotype and function. (nature.com)
  • Low AKR1B10 expression induced M2 macrophage polarization and promoted the malignant phenotype of GC. (portlandpress.com)
  • However, changes in expression of miRNA may be secondary to the tumor phenotype. (bvsalud.org)
  • The Working Group concluded that the animal mammary tumors associated with exposure to atrazine involve a non-DNA-reactive, hormonally mediated mechanism that is not relevant to humans. (who.int)
  • RT can directly induce cancer cell death through various mechanisms, such as apoptosis, necrosis, and autophagy. (nature.com)
  • TRIM13-induced NSCLC cell apoptosis was attenuated by a caspase-3 inhibitor Ac-DEVD-CHO, suggesting that TRIM13 induced cell apoptosis partially through a caspase-3-dependent pathway. (cancerindex.org)
  • Therapeutic efficacy of these radionuclides depends on the E max , physical half-life, and residence time of the radiolabel in the tumor. (snmjournals.org)
  • Accordingly, the radiation dose to the tumor, correlating with the therapeutic efficacy of pretargeted RCC, can be enhanced substantially. (snmjournals.org)
  • So far, radioimmunotherapy (RIT) has only induced significant therapeutic effect in patients with hematologic tumors, presumably due to their relatively high radiosensitivity ( 4 , 5 ). (snmjournals.org)
  • Therapeutic human papillomavirus (HPV) vaccine candidates constructed with iBioModulator provided superior protection from HPV-16 E7-induced tumors and extended survival in a mouse model when compared with vaccination with native E7 protein alone. (globenewswire.com)
  • The HPV tumor protection was both prophylactic and therapeutic. (globenewswire.com)
  • Effective therapeutic vaccination to treat HPV-induced cancer has been a long-desired but difficult to achieve objective of healthcare professionals. (globenewswire.com)
  • With the ability of the mAbs to demonstrate therapeutic antitumor activity in those patients with relatively advanced malignancies, the term tumor specific was introduced. (jcancer.org)
  • As such we plan to eventually employ the therapeutic mAbs in combination with chemotherapy as a means of enhancing the immunogenicity of the tumor system being treated and to possibly weaken the malignant growth for easier destruction by the mAb. (jcancer.org)
  • before resection of the primary tumor and then postoperatively every 6-12 mo, resulting in three to five samples per patient. (lu.se)
  • Any molecule capable of being recognized by the immune system is considered an antigen. (msdmanuals.com)
  • A key role of the immune system is detection of these antigens to permit subsequent targeting for eradication. (msdmanuals.com)
  • ITI-4000 is an innovative and novel approach to an EBV-tumor vaccine," says Rich Ambinder, M.D., Ph.D., Director of the Division of Hematologic Malignancies and Professor of Oncology at Johns Hopkins, Immunomic's Scientific Advisory Board member, and expert in viral-driven malignancies. (biospace.com)
  • In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. (stockhouse.com)
  • 4 According to the number of tumor-infiltrating lymphocytes, tumors can be divided into three phenotypes: immune-inflamed, immune-excluded, and immune-desert types. (nature.com)
  • It unlocks novel dimensions by uncovering elusive cell populations and tumor heterogeneities for early detection, unraveling mechanisms of treatment resistance, tailoring therapies to individuals, and illuminating metastasis and cachexia pathways, thereby opening fresh avenues for preventive strategies. (frontiersin.org)
  • To characterize biomarkers in neural tumors, we analyzed the acidic lipid fractions of 13 neural tumor cell lines using enzyme-linked immunoabsorbent assay (ELISA) and high-performance thin-layer chromatography (HPTLC) immunostaining. (karger.com)
  • The results from this prevali- the field of cancer biomarkers (11-13), and that approach was dation study showed that patients could be classified into high- adopted here to define predictive serum biomarkers associated versus low-risk groups for developing metastatic breast cancer with tumor relapse in breast cancer patients. (lu.se)
  • Inoculated tumors grew significantly slower in aFP-treated groups (aFP and aFP + anti-PD-1 groups) and complete remission was observed in the aFP-treated groups. (medicalrecords.com)
  • We are finding that CD-19 directed CARTs for relapsed/refractory DLBCL can induce remarkably durable remissions and cures in patients who previously had limited treatment options after being chemotherapy refractory, with an associated low chance of achieving remission and poor prognosis. (medpagetoday.com)
  • Tumor antigens are hypothesized to evoke both a humoral and a cellular immune response that leads to blistering in mucosa and other epithelia. (medscape.com)
  • Other receptors able to bind induced-self antigens are NKG2C, NKG2E, NKG2F (CD94) or some NCRs (e.g. (wikipedia.org)
  • In this approach a nonradiolabeled bispecific monoclonal antibody (bs-mAb) with antitumor-associated antigen (TAA) and antihapten specificity is injected in the first phase. (snmjournals.org)
  • In fact, this type of antigen was the target of the first monoclonal antibody therapy for a malignancy (B-cell lymphoma) in 1982. (oncolink.org)
  • Strain susceptibility and resistance to 1,2-dimethylhydrazine-induced enteric tumors in germfree rats (40146). (cdc.gov)
  • Voss C, Zerban H, Bannasch P, Berger MR. Lifelong exposure to di-(2-ethylhexyl)-phthalate induces tumors in liver and testes of Sprague-Dawley rats. (who.int)
  • To improve the residence time of the iodine label in the tumor, a new bivalent peptide was synthesized that is peptidase resistant and consists of 4 d -amino acids ( d -a.a. peptide). (snmjournals.org)
  • The maximum uptake and retention of 125 I-labeled l -a.a. peptide in the tumor were significantly lower compared with that of the 111 In-labeled l -a.a. peptide. (snmjournals.org)
  • In contrast, the tumor uptake and retention of the 125 I-labeled d -a.a. peptide) were similar to that of the 111 In-labeled l -a.a. peptide but were superior at later time points. (snmjournals.org)
  • The biodistribution of the radioiodinated d -a.a. peptide was highly similar to that of the 111 In-labeled d -a.a. peptide, and both radiolabeled peptides were retained significantly better in the tumor than the 111 In-labeled l -a.a. peptide. (snmjournals.org)
  • Uptake and retention in the tumor of the iodinated peptide after pretargeting with a bs-mAb can be significantly improved using d -a.a. peptides. (snmjournals.org)
  • iBioModulator has been used as a fusion to express peptide or protein domain antigens in a number of other successful vaccine candidates, including those for anthrax, plague, sleeping sickness and influenza. (globenewswire.com)
  • We conducted a pilot randomized phase I trial in PC patients to determine the peptide dose required to induce an optimal CD8 + T cell response. (bmj.com)
  • In certain lymphomas, the immunoglobulin antigen that the lymphoid cell is supposed to be producing becomes mutated, and hence a potential target for vaccines. (oncolink.org)
  • Antitumor immunity elicited by tumor-APCs was synergistic with immune checkpoint inhibitors. (lu.se)
  • Most nasopharyngeal carcinomas express Epstein-Barr nuclear antigen 1 (EBNA1), a sequence-specific DNA-binding protein involved in maintenance of the episomal virus genome that is required for EBV latency and associated transformation. (biospace.com)
  • As proof-of-concept, the established target antigen CD44 was identified as a commonly and abundantly expressed surface protein with high endocytic activity. (lu.se)
  • In this respect, in contrast to predictors based for each serum protein was determined by comparing the samples upon tumor characteristics at the time of surgery, serum is a par- collected at the primary operation and then 3-6 mo later. (lu.se)
  • In addition, we have analyzed serum antibody titers against SGPG, GD3, and OAc-GD3 in patients with neural tumors by ELISA and HPTLC immunostaining. (karger.com)
  • This includes the amount of shed antigen in the serum at the time of treatment that could initiate immune complex formation as well as the shedding of inhibitory material into the serum possibly effecting an immune response. (jcancer.org)
  • To our knowledge, this is the first time to report the role of TRIM28 in regulating the expression of cancer/testis antigen MAGEC2. (biomedcentral.com)
  • Low AKR1B10 expression induces M2 macrophage polarization and promotes the malignant transformation of GC. (portlandpress.com)
  • Abnormal synaptic function leads to the weakening of cognitive functions such as learning and memory, accompanied by abnormal expression of Kal-7, which in turn induces a variety of neurodegenerative diseases. (bvsalud.org)
  • We could validate these findings by immunofluorescence analyses in patient tumors and by increased expression in the hypoxic core of GBM spheroids. (lu.se)
  • Moreover, other recognition targets exist, for example ligands induced on human macrophages by TLR stimulation. (wikipedia.org)
  • So far, it is not known which tumor features are reflected by the different imaging modalities and whether this has an impact on the clinical outcome and prognosis of patients. (uni-regensburg.de)
  • ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. (biospace.com)
  • Tumor resection and serial stereotactic biopsies will be performed using an image guided neuronavigation system. (uni-regensburg.de)
  • Probably the most studied receptor involved in recognition of induced-self antigens is NKG2D. (wikipedia.org)
  • CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. (nature.com)
  • Antigens are foreign substances that evoke an immune response. (medscape.com)